Hemogenyx raises £340,000 for leukaemia clinical trials
Portfolio Pulse from
Hemogenyx Pharmaceuticals PLC has raised £340,000 through a share placement to fund leukaemia clinical trials. The placement involved 100,000 new shares at 340p each, underwritten by a single institutional investor who also received 50,000 warrants exercisable at 500p per share.
January 08, 2025 | 8:00 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Hemogenyx Pharmaceuticals raised £340,000 for leukaemia trials through a share placement, potentially impacting its stock price.
The successful fundraising through share placement indicates investor confidence and provides capital for clinical trials, which could positively impact the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80